Literature DB >> 32364822

Association Between Maternal Obesity and Group B Streptococcus Colonization in a National U.S. Cohort.

Kartik K Venkatesh1, Catherine J Vladutiu1, Robert A Strauss1, John M Thorp2, Jeffrey S A Stringer3, David M Stamilio1, Brenna L Hughes4, Sarah Dotters-Katz4.   

Abstract

Objective: To investigate the association between maternal obesity as measured by prepregnancy body mass index (BMI) and group B streptococcus (GBS) colonization.
Methods: We conducted a secondary analysis from the Consortium on Safe Labor Study (CSL) in the United States cohort study (2002-2008). Pregnant women with deliveries at ≥37 weeks of gestation who attempted labor were included (115,070 assessed deliveries). The association between maternal prepregnancy BMI, categorized as normal weight or below (<25 kg/m2), overweight (25 to <30 kg/m2), class I obesity (30 to <35 kg/m2), class II obesity (35 to <40 kg/m2), and class III obesity (≥40 kg/m2), and GBS colonization was modeled using logistic regression with generalized estimating equations. Models adjusted for maternal age, parity, race, pregestational diabetes, insurance status, study site/region, and year of delivery.
Results: The overall prevalence of GBS colonization was 20.5% (23,625/115,070), which increased with rising maternal BMI, normal weight 19.3% (13,543/70,098), overweight 20.8% (5,353/25,733), class I obesity 23.0% (2,596/11,275), class II obesity 26.1% (1,270/4,850), and class III obesity 27.7% (863/3,114). In multivariable analysis, increasing maternal obesity severity was associated with higher odds of GBS colonization, namely overweight (adjusted odds ratio [AOR]: 1.09, 95% confidence interval [CI]: 1.05-1.13), class I obesity (AOR: 1.20, 95% CI: 1.15-1.26), class II obesity (AOR: 1.42, 95% CI: 1.33-1.51), and class III obesity (AOR: 1.50; 95% CI: 1.38-1.62) compared with normal weight. In secondary analyses, these associations persisted when stratified by maternal race. Conclusions: In a national U.S. sample, increasing maternal obesity severity as assessed by prepregnancy BMI was associated with a higher likelihood of maternal GBS colonization during pregnancy.

Entities:  

Keywords:  GBS; body mass index; group B streptococcus; obesity; pregnancy

Mesh:

Year:  2020        PMID: 32364822      PMCID: PMC7757598          DOI: 10.1089/jwh.2019.8139

Source DB:  PubMed          Journal:  J Womens Health (Larchmt)        ISSN: 1540-9996            Impact factor:   2.681


  32 in total

1.  Prospective studies of group B streptococcal infections in infants.

Authors:  M A Pass; B M Gray; S Khare; H C Dillon
Journal:  J Pediatr       Date:  1979-09       Impact factor: 4.406

2.  Microbial ecology: human gut microbes associated with obesity.

Authors:  Ruth E Ley; Peter J Turnbaugh; Samuel Klein; Jeffrey I Gordon
Journal:  Nature       Date:  2006-12-21       Impact factor: 49.962

3.  An obesity-associated gut microbiome with increased capacity for energy harvest.

Authors:  Peter J Turnbaugh; Ruth E Ley; Michael A Mahowald; Vincent Magrini; Elaine R Mardis; Jeffrey I Gordon
Journal:  Nature       Date:  2006-12-21       Impact factor: 49.962

4.  Racial disparities in intrapartum group B Streptococcus colonization: a higher incidence of conversion in African American women.

Authors:  Melissa H Spiel; Michele R Hacker; Miriam J Haviland; Bethany Mulla; Elizabeth Roberts; Laura E Dodge; Brett C Young
Journal:  J Perinatol       Date:  2019-01-11       Impact factor: 2.521

5.  Obesity as an independent risk factor for group B streptococcal colonization.

Authors:  Mitchell D Alvareza; Akila Subramaniam; Ying Tang; Rodney K Edwards
Journal:  J Matern Fetal Neonatal Med       Date:  2016-12-20

6.  Risk factors for group B streptococcal genitourinary tract colonization in pregnant women.

Authors:  Renee D Stapleton; Jeremy M Kahn; Laura E Evans; Cathy W Critchlow; Carolyn M Gardella
Journal:  Obstet Gynecol       Date:  2005-12       Impact factor: 7.661

7.  The effects of labor and delivery on maternal and neonatal outcomes in term twins: a retrospective cohort study.

Authors:  D J Wenckus; W Gao; M A Kominiarek; I Wilkins
Journal:  BJOG       Date:  2014-02-28       Impact factor: 6.531

8.  Evaluation of universal antenatal screening for group B streptococcus.

Authors:  Melissa K Van Dyke; Christina R Phares; Ruth Lynfield; Ann R Thomas; Kathryn E Arnold; Allen S Craig; Janet Mohle-Boetani; Ken Gershman; William Schaffner; Susan Petit; Shelley M Zansky; Craig A Morin; Nancy L Spina; Kathryn Wymore; Lee H Harrison; Kathleen A Shutt; Joseph Bareta; Sandra N Bulens; Elizabeth R Zell; Anne Schuchat; Stephanie J Schrag
Journal:  N Engl J Med       Date:  2009-06-18       Impact factor: 91.245

9.  High maternal body mass index increases the risk of neonatal early onset group B streptococcal disease.

Authors:  Stellan Håkansson; Karin Källen
Journal:  Acta Paediatr       Date:  2008-07-18       Impact factor: 2.299

Review 10.  An overview of global GBS epidemiology.

Authors:  Kirsty Le Doare; Paul T Heath
Journal:  Vaccine       Date:  2013-08-28       Impact factor: 3.641

View more
  3 in total

Review 1.  Group B streptococcal infection of the genitourinary tract in pregnant and non-pregnant patients with diabetes mellitus: An immunocompromised host or something more?

Authors:  Lynsa M Nguyen; Joel I Omage; Kristen Noble; Kelsey L McNew; Daniel J Moore; David M Aronoff; Ryan S Doster
Journal:  Am J Reprod Immunol       Date:  2021-10-19       Impact factor: 3.886

2.  Epidemiological Trends of Racial Differences in Early- and Late-onset Group B Streptococcus Disease in Tennessee.

Authors:  Lubna Hamdan; Simon Vandekar; Andrew J Spieker; Herdi Rahman; Danielle Ndi; Emily S Shekarabi; Jyotsna Thota; Danielle A Rankin; Zaid Haddadin; Tiffanie Markus; David M Aronoff; William Schaffner; Jennifer A Gaddy; Natasha B Halasa
Journal:  Clin Infect Dis       Date:  2021-12-06       Impact factor: 20.999

3.  Jiedu-Yizhi Formula Alleviates Neuroinflammation in AD Rats by Modulating the Gut Microbiota.

Authors:  Jiale Wang; Xiaoting Zhu; Yuhui Li; Wenping Guo; Mingquan Li
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-31       Impact factor: 2.650

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.